Resumen
La trombocitopenia inmune es un trastorno autoinmunitario el cual lleva a destrucción de plaquetas, y recuentos plaquetarios bajos. Las trasfusiones de plaquetas son necesarias para prevenir las complicaciones hemorrágicas, y la falla en la obtención de nivel adecuado de plaquetas circulantes afecta adversamente la supervivencia. Mediante la transfusión de plaquetas se puede limitar el sangrado, pero de modo transitorio (por algunas horas), llegando a requerirse trasfusiones a repetición. Cada vez se ha descrito más acerca del uso de trasfusión de plaquetas en pacientes hospitalizados con trombocitopenia inmune. El papel de las transfusiones de plaquetas en el tratamiento de la trombocitopenia inmune sigue siendo de controversia, y se cree que su beneficio clínico podría estar limitado por la supervivencia más corta de las plaquetas transfundidas. Se plantea como objetivo revisar el estado del arte de las transfusiones plaquetarias en trombocitopenia inmune en población adulta, haciendo énfasis en desenlaces intrahospitalarios.
Referencias
Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346(13):995-1008. https://doi.org/10.1056/NEJMra010501
Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780-3817. https://doi.org/10.1182/bloodadvances.2019000812
Fogarty PF, Segal JB. The epidemiology of immune thrombocytopenic purpura. Curr Opin Hematol. 2007;14(5):515-9. https://doi.org/10.1097/MOH.0b013e3282ab98c7
Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190-4207. https://doi.org/10.1182/blood-2010-08-302984
Hanson SR, Slichter SJ. Platelet kinetics in patients with bone marrow hypoplasia: evidence for a fixed platelet requirement. Blood. 1985;66(5):1105-9. https://doi.org/ 10.1182/blood.v66.5.1105.1105
Storb R, Prentice RL, Buckner CD, Clift RA, Appelbaum F, Deeg J, et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med. 1983;308(6):302-307. https://doi.org/10.1056/NEJM198302103080602
Cirasino L, Robino AM, Cattaneo M, Pioltelli PE, Pogliani EM, Terranova L, et al. Appropriate hospital management of adult immune thrombocytopenic purpura patients in major Italian institutions in 2000-2002: a retrospective analysis. Blood Coagul Fibrinolysis. 2010;21(1):77-84. https://doi.org/10.1097/MBC.0b013e328332dbb6
Stoll D, Cines DB, Aster RH, Murphy S. Platelet kinetics in patients with idiopathic thrombocytopenic purpura and moderate thrombocytopenia. Blood. 1985;65(3):584-8. https://doi.org/10.1182/blood.v65.3.584.584
Baumann MA, Menitove JE, Aster RH, Anderson T. Urgent treatment of idiopathic thrombocytopenic purpura with single-dose gammaglobulin infusion followed by platelet transfusion. Ann Intern Med. 1986;104(6):808-9. https://doi.org/10.7326/0003-4819-104-6-808
Salama A, Kiesewetter H, Kalus U, Movassaghi K, Meyer O. Massive platelet transfusion is a rapidly effective emergency treatment in patients with refractory autoimmune thrombocytopenia. Thromb Haemost. 2008;100(5):762-5. https://doi.org/10.1160/TH08-06-0418
Spahr JE, Rodgers GM. Treatment of immune-mediated thrombocytopenia purpura with concurrent intravenous immunoglobulin and platelet transfusion: a retrospective review of 40 patients. Am J Hematol. 2008;83(2):122-5. https://doi.org/10.1002/ajh.21060
Danese MD, Lindquist K, Gleeson M, Deuson R, Mikhael J. Cost and mortality associated with hospitalizations in patients with immune thrombocytopenic purpura. Am J Hematol. 2009;84(10):631-635. https://doi.org/10.1002/ajh.21500
Abrahm J, Ellman L. Platelet transfusion in immune thrombocytopenic purpura. JAMA. 1976;236(16):1847.
Carr JM, Kruskall MS, Kaye JA, Robinson SH. Efficacy of platelet transfusions in immune thrombocytopenia. Am J Med. 1986;80(6):1051-4. https://doi.org/10.1016/0002-9343(86)90664-9
Chandramouli NB, Rodgers GM. Prolonged immunoglobulin and platelet infusion for treatment of immune thrombocytopenia. Am J Hematol. 2000;65(1):85-6. https://doi.org/10.1002/1096-8652(200009)65:1<85::aid-ajh17>3.0.co;2-9
Goel R, Chopra S, Tobian AAR, Ness PM, Frank SM, Cushing M, et al. Platelet transfusion practices in immune thrombocytopenia related hospitalizations. Transfusion. 2019;59(1):169-176. https://doi.org/10.1111/trf.15069
Solís M, Rivera A. Solís-Mancilla M, Rivera-Trujillo A, Hernández-Rodríguez S, Carranza Madrigal J. Idoneidad de la transfusión plaquetaria en pacientes con trombocitopenia inmunitaria primaria. Hematol Méx. 2019;20(3):189-97. https://doi.org/10.24245/rhema
Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med. 2000;160(11):1630-8. https://doi.org/10.1001/archinte.160.11.1630
Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866. https://doi.org/10.1182/bloodadvances.2019000966
Mollison PL, Engelfriet CP, Contreras M, editores. Blood transfusion in clinical medicine. 10.ª ed. Malden (MA): Blackwell Science; 1997.
McMillan R. Therapy for adults with refractory chronic immune thrombocytopenic purpura. Ann Intern Med. 1997;126(4):307-14. https://doi.org/10.7326/0003-4819-126-4-199702150-00007
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Derechos de autor 2022 Juan Sebastián Frías Ordóñez